Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

To find out about drugs in current trials and when they come off patent for horizon scanning of likely changes to treatment pathways in the UK

— Charity, UK

For information about medicines -- patent expiration dates, title, terms, etc.

— Pharmaceutical regulatory affairs, Mexico

To find Australian patent expiry dates for pharmaceutical products

— Pharmaceutical wholesaler, Australia

To conduct research on drug patent expirations

— Data management / business information, specialty pharmaceuticals, China

For patent explorations of some brand products

— Pharma advertising, Russia

Generated: May 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,466,159

« Back to Dashboard

Which drugs does patent 8,466,159 protect, and when does it expire?


Patent 8,466,159 protects VIEKIRA PAK (COPACKAGED) and VIEKIRA XR and is included in two NDAs.

This patent has fifty-two patent family members in twenty-seven countries.

Summary for Patent: 8,466,159

Title:Methods for treating HCV
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
Inventor(s): Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Gurnee, IL), Cohen; Daniel E. (Wilmette, IL), Podsadecki; Thomas J. (Chicago, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:13/603,022
Patent Claim Types:
see list of patent claims		Use;

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes8,466,159► Subscribe TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes8,466,159► Subscribe TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,466,159

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,969,357Methods for treating HCV► Subscribe
8,680,106Methods for treating HCV► Subscribe
9,452,194Methods for treating HCV► Subscribe
8,853,176Methods for treating HCV► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,466,159

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China103826627► Subscribe
China104383541► Subscribe
China105363035► Subscribe
Germany12189198► Subscribe
Germany112012002748► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

For information on products (NDAs and ANDAs) that I may be interested in developing, licensing or acquiring

— Executive, specialty pharmaceutical company, USA

To be informed abut patent protection and patent challenges

— Business development / Licensing / Marketing & sales, Italy

To follow patent expirations for generic production purposes

— Pharmacist, Tunisia

To find information on expiration dates of patents in the Netherlands

— Hospital pharmacist, Netherlands

To get patent/product expiration details and freedom-to-operate opportunities

— API development, India

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot